Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Insmed Incorporated (INSM) Report Updated: Nov 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

Insmed Incorporated (INSM)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: EBS, EGRX, ZIOP, NBIX

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: B down no change
Last Week: B same upgrade
Two Weeks Ago: C up downgrade
service keys

Insmed Incorporated© quotemedia

Company Profile

Insmed Incorporated, a development-stage biopharmaceutical company, develops inhaled treatments for serious lung infections. Its primary product candidate, ARIKACE is a differentiated inhaled antibiotic supported by positive Phase II results for treating serious lung infections due to susceptible bacteria. The company’s IPLEX is a proprietary protein product that is being evaluated in the treatment of retinopathy of prematurity. It out licensed the rights of three early stage development products, including Inhaled CISPLATIN Lipid Complex, rhIGFBP-3, and INSM-18. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.

Recent News: Insmed Incorporated